Company news from the 09/12/06 News Brief

MedImmune broke ground on a $250 million, multi-phase expansion project at its Frederick, MD, manufacturing site. The expansion will increase MedImmune's manufacturing capacity for monoclonal antibodies including Synagis, which it introduced to the market in 1998 and other products in the company's pipeline.
You must be a registered member of MMM to post a comment.